陇神戎发股价下跌3.06% 新药临床试验进展受关注

Core Viewpoint - The stock price of Longshen Rongfa has decreased by 3.06% to 11.72 yuan as of August 5, 2025, with a trading volume of 567 million yuan and a turnover rate of 15.88% [1] Company Overview - Longshen Rongfa operates in the pharmaceutical and biotechnology industry, focusing on the research, development, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company’s subsidiary, Puan Pharmaceutical, is currently conducting clinical trials for its modified new drug, Bupropion oral dissolving film [1] Shareholder and Market Activity - As of July 31, 2025, the number of shareholders for Longshen Rongfa is 28,861, reflecting a decrease of 1.05% from the previous period [1] - The market is closely monitoring the progress of the new drug development, particularly the ongoing clinical trials for Bupropion oral dissolving film [1] Capital Flow - On August 5, 2025, the net outflow of main funds was 38.71 million yuan, accounting for 1.09% of the circulating market value [1] - Over the past five days, the cumulative net inflow of main funds reached 12.78 million yuan [1]